Incyte (INCY) News Today $62.42 -0.36 (-0.58%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Morgan Stanley Cuts Incyte (NASDAQ:INCY) Price Target to $65.00Morgan Stanley dropped their target price on Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday.March 25 at 8:12 AM | marketbeat.comIncyte Co. (NASDAQ:INCY) Shares Purchased by Sound Shore Management Inc. CTSound Shore Management Inc. CT raised its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 98.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,201,089 shares of the biopharmaceutical company's stock after buying an additMarch 25 at 6:49 AM | marketbeat.comCannon Global Investment Management LLC Takes $449,000 Position in Incyte Co. (NASDAQ:INCY)Cannon Global Investment Management LLC acquired a new stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,500 shares of the biopharmaceuticalMarch 25 at 6:05 AM | marketbeat.com7,978 Shares in Incyte Co. (NASDAQ:INCY) Bought by Fox Run Management L.L.C.Fox Run Management L.L.C. bought a new stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 7,978 shares of the biopharmaceutical company's stock, valued at appMarch 25 at 4:56 AM | marketbeat.comTeacher Retirement System of Texas Raises Position in Incyte Co. (NASDAQ:INCY)Teacher Retirement System of Texas boosted its position in Incyte Co. (NASDAQ:INCY - Free Report) by 11.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 49,581 shares of the biopharmaceutical company's stock after acquiring an additional 5,135 shareMarch 25 at 4:12 AM | marketbeat.comNatixis Advisors LLC Makes New Investment in Incyte Co. (NASDAQ:INCY)Natixis Advisors LLC acquired a new position in Incyte Co. (NASDAQ:INCY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 24,905 shares of the biopharmaceutical company's stock, valuMarch 25 at 3:36 AM | marketbeat.comIncyte price target lowered to $65 from $69 at Morgan StanleyMarch 24 at 3:53 PM | markets.businessinsider.comIncyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa TreatmentMarch 24 at 10:52 AM | msn.com6,598 Shares in Incyte Co. (NASDAQ:INCY) Purchased by AXQ Capital LPAXQ Capital LP acquired a new stake in Incyte Co. (NASDAQ:INCY - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 6,598 shares of the biopharmaceutical company's stock, valued at approximately $456,000. A nuMarch 24 at 5:42 AM | marketbeat.comNorthwest & Ethical Investments L.P. Sells 15,820 Shares of Incyte Co. (NASDAQ:INCY)Northwest & Ethical Investments L.P. trimmed its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 51.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,944 shares of the biopharmaceutical company'March 23 at 5:14 AM | marketbeat.comRoyal London Asset Management Ltd. Grows Stake in Incyte Co. (NASDAQ:INCY)Royal London Asset Management Ltd. grew its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 179,525 shares of the biopharmaceutical company's stock after buying an addiMarch 23 at 4:33 AM | marketbeat.comIncyte Co. (NASDAQ:INCY) Stake Lowered by Sector Gamma ASSector Gamma AS reduced its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 23.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 197,400 shares of the biopharmaceutical company'March 22 at 6:51 AM | marketbeat.comMonday.com, Incyte, Lucid, Bloom, EQT: Trending by AnalystsMarch 22 at 5:24 AM | tipranks.comIncyte Co. (NASDAQ:INCY) Position Reduced by Intech Investment Management LLCIntech Investment Management LLC cut its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 53.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,028 shares of the biopharmaceutical companyMarch 22 at 4:44 AM | marketbeat.comIncyte Had a Bad Week. Investors Are Used to It.March 21, 2025 | msn.comWhy Incyte Stock Was Tanking This WeekMarch 21, 2025 | fool.comWilliam Blair Analysts Boost Earnings Estimates for IncyteIncyte Co. (NASDAQ:INCY - Free Report) - Stock analysts at William Blair raised their Q2 2025 earnings estimates for shares of Incyte in a research report issued to clients and investors on Tuesday, March 18th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company willMarch 21, 2025 | marketbeat.comGenerali Asset Management SPA SGR Purchases Shares of 38,487 Incyte Co. (NASDAQ:INCY)Generali Asset Management SPA SGR purchased a new stake in Incyte Co. (NASDAQ:INCY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 38,487 shares of the biopharmaceutical company's stock, valued atMarch 21, 2025 | marketbeat.comWilliam Blair Issues Optimistic Forecast for Incyte EarningsMarch 21, 2025 | americanbankingnews.comWilliam Blair Issues Positive Forecast for Incyte EarningsMarch 21, 2025 | americanbankingnews.comKoss Olinger Consulting LLC Invests $1.68 Million in Incyte Co. (NASDAQ:INCY)Koss Olinger Consulting LLC purchased a new position in Incyte Co. (NASDAQ:INCY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 24,283 shares of the biopharmaceutical company's stock, valued at approximately $1,677,000. A numbeMarch 20, 2025 | marketbeat.comVinva Investment Management Ltd Purchases 100,151 Shares of Incyte Co. (NASDAQ:INCY)Vinva Investment Management Ltd grew its position in Incyte Co. (NASDAQ:INCY - Free Report) by 827.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 112,259 shares of the biopharmaceutical company's stoMarch 20, 2025 | marketbeat.comFY2025 Earnings Estimate for Incyte Issued By William BlairIncyte Co. (NASDAQ:INCY - Free Report) - Equities research analysts at William Blair boosted their FY2025 earnings per share (EPS) estimates for Incyte in a report issued on Tuesday, March 18th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings ofMarch 20, 2025 | marketbeat.comCompass Ion Advisors LLC Has $960,000 Stock Holdings in Incyte Co. (NASDAQ:INCY)Compass Ion Advisors LLC increased its stake in Incyte Co. (NASDAQ:INCY - Free Report) by 293.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,894 shares of the biopharmaceutical company's stockMarch 20, 2025 | marketbeat.comTruist Financial Has Lowered Expectations for Incyte (NASDAQ:INCY) Stock PriceMarch 20, 2025 | americanbankingnews.comGuggenheim Downgrades Incyte (NASDAQ:INCY) to NeutralMarch 20, 2025 | americanbankingnews.comIncyte Co. (NASDAQ:INCY) EVP Sells $1,340,735.83 in StockIncyte Co. (NASDAQ:INCY - Get Free Report) EVP Barry P. Flannelly sold 19,807 shares of the business's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the sale, the executive vice president now owns 33,567 shares of the company's stock, valued at approximately $2,272,150.23. This trade represents a 37.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.March 19, 2025 | marketbeat.comSiddhi MahatoleMarch 19, 2025 | reuters.comIncyte (INCY) was downgraded to a Hold Rating at William BlairMarch 19, 2025 | markets.businessinsider.comIncyte (NASDAQ:INCY) Price Target Lowered to $72.00 at Truist FinancialTruist Financial lowered their target price on Incyte from $74.00 to $72.00 and set a "hold" rating for the company in a research note on Tuesday.March 19, 2025 | marketbeat.comIncyte (NASDAQ:INCY) Rating Lowered to "Neutral" at GuggenheimGuggenheim cut Incyte from a "buy" rating to a "neutral" rating in a report on Tuesday.March 19, 2025 | marketbeat.comIncyte (NASDAQ:INCY) Rating Lowered to Market Perform at William BlairWilliam Blair lowered shares of Incyte from an "outperform" rating to a "market perform" rating in a research report on Tuesday.March 19, 2025 | marketbeat.comIncyte Co. (NASDAQ:INCY) EVP Barry P. Flannelly Sells 19,807 SharesMarch 19, 2025 | insidertrades.comWilliam Blair Downgrades Incyte (NASDAQ:INCY) to Market PerformMarch 19, 2025 | americanbankingnews.comIncyte price target lowered to $72 from $74 at TruistMarch 18, 2025 | markets.businessinsider.comIncyte: Still A 'Buy' Despite HS Treatment Data With PovorcitinibMarch 18, 2025 | seekingalpha.comIncyte’s Povorcitinib Shows Promise but Faces Competitive and Market Challenges, Leading to Hold RatingMarch 18, 2025 | tipranks.comIncyte (NASDAQ:INCY) Shares Gap Down - Here's What HappenedIncyte (NASDAQ:INCY) Shares Gap Down - Should You Sell?March 18, 2025 | marketbeat.comOil pressures, Robinhood, Incyte: Market MinuteMarch 18, 2025 | finance.yahoo.comIncyte downgraded to Market Perform from Outperform at William BlairMarch 18, 2025 | markets.businessinsider.comIncyte (INCY) Receives a Hold from Wells FargoMarch 18, 2025 | markets.businessinsider.comIncyte downgraded to Neutral at Guggenheim on trial results for skin disease treatmentMarch 18, 2025 | seekingalpha.comIncyte’s Stock Downgraded to Sell Amid Disappointing Drug Data and Market ChallengesMarch 18, 2025 | tipranks.comHaven Capital Group Inc. Makes New Investment in Incyte Co. (NASDAQ:INCY)Haven Capital Group Inc. purchased a new stake in Incyte Co. (NASDAQ:INCY - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 20,142 shares of the biopharmaceutical company's stock, valued at approximately $1,391,000. Incyte comprises 1.3% ofMarch 18, 2025 | marketbeat.comIncyte’s Promising Phase 3 Results and Market Potential Drive Buy RatingMarch 18, 2025 | tipranks.comIncyte Co. (NASDAQ:INCY) Shares Purchased by Delphi Management Inc. MADelphi Management Inc. MA increased its position in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 631.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,783 shares of the biopharmaceutical cMarch 18, 2025 | marketbeat.comSwiss National Bank Sells 20,800 Shares of Incyte Co. (NASDAQ:INCY)Swiss National Bank cut its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 4.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 462,474 shares of the biopharmaceutical company's stock after selling 20,800 shares during the period. Swiss NaMarch 18, 2025 | marketbeat.comProficio Capital Partners LLC Purchases Shares of 51,388 Incyte Co. (NASDAQ:INCY)Proficio Capital Partners LLC acquired a new position in Incyte Co. (NASDAQ:INCY - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 51,388 shares of the biopharmaceutical coMarch 18, 2025 | marketbeat.comIncyte stock decline after results an ‘overreaction,” says Wolfe ResearchMarch 17, 2025 | markets.businessinsider.comLeerink says Incyte’s povo trial results disappoint, drug likely to be approvedMarch 17, 2025 | markets.businessinsider.com Remove Ads Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Media Mentions By Week INCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INCY News Sentiment▼0.430.63▲Average Medical News Sentiment INCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INCY Articles This Week▼5313▲INCY Articles Average Week Remove Ads Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today BioMarin Pharmaceutical News Today Neurocrine Biosciences News Today Exelixis News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INCY) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INCY Stock Free INCY Stock Alerts